Bristol Myers Squibb Company (NYSE:BMY - Get Free Report) EVP Bartie Wendy Short sold 378 shares of Bristol Myers Squibb stock in a transaction that occurred on Saturday, August 2nd. The stock was sold at an average price of $44.23, for a total value of $16,718.94. Following the completion of the sale, the executive vice president directly owned 5,066 shares in the company, valued at $224,069.18. This represents a 6.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Bristol Myers Squibb Stock Up 1.1%
NYSE BMY traded up $0.50 during trading hours on Thursday, hitting $45.32. 11,839,864 shares of the company were exchanged, compared to its average volume of 13,525,695. The company has a 50 day moving average of $47.41 and a two-hundred day moving average of $52.06. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 52-week low of $42.96 and a 52-week high of $63.33. The firm has a market cap of $92.24 billion, a price-to-earnings ratio of 18.27, a PEG ratio of 2.35 and a beta of 0.36.
Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%. Bristol Myers Squibb's revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.07 EPS. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.
Bristol Myers Squibb Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.5%. The ex-dividend date of this dividend was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is currently 100.00%.
Wall Street Analyst Weigh In
A number of research firms have commented on BMY. Daiwa America downgraded Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday. Jefferies Financial Group cut their price objective on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Piper Sandler began coverage on Bristol Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective on the stock. William Blair reiterated a "market perform" rating on shares of Bristol Myers Squibb in a report on Friday, April 25th. Finally, UBS Group cut their price objective on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb has an average rating of "Hold" and an average price target of $56.38.
View Our Latest Analysis on Bristol Myers Squibb
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in BMY. ProShare Advisors LLC boosted its position in shares of Bristol Myers Squibb by 10.4% in the 2nd quarter. ProShare Advisors LLC now owns 392,668 shares of the biopharmaceutical company's stock valued at $18,177,000 after purchasing an additional 37,125 shares during the period. King Luther Capital Management Corp boosted its position in shares of Bristol Myers Squibb by 115.2% in the 2nd quarter. King Luther Capital Management Corp now owns 536,588 shares of the biopharmaceutical company's stock valued at $24,839,000 after purchasing an additional 287,201 shares during the period. Midwest Trust Co acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at about $5,671,000. Acadian Asset Management LLC boosted its position in shares of Bristol Myers Squibb by 958.5% in the 2nd quarter. Acadian Asset Management LLC now owns 1,775,057 shares of the biopharmaceutical company's stock valued at $82,161,000 after purchasing an additional 1,607,363 shares during the period. Finally, CSM Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at about $17,696,000. 76.41% of the stock is owned by institutional investors and hedge funds.
Bristol Myers Squibb Company Profile
(
Get Free Report)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Further Reading
Before you consider Bristol Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.
While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.